Table 4

Comparison of studies investigating miRNAs from blood samples (serum or plasma) of patients with FTD and/or ALS

Freischmidt et al 2014*11 Sheinerman et al 2017†17 Piscopo et al 2018†18 Grasso et al 2019†19 Magen et al 2020†20 This study†
CohortSeparate sporadic/genetic‡Not mentionedSporadicSporadicMixed sporadic/genetic§ C9orf72
Patients, n=
9/13 genetic
14 sporadic
50 FTD
50 ALS
5410/4852/117 FTD
115 ALS
Presymptomatic carriers, n=1845
Methods of analysisMicroarrays37 selected miRNAs
9 selected miRNAs
752 selected miRNAs
Large scale sequencing
Large scale sequencing (RNA-seq)
Major deregulated miRNAsmiR-4745-5p miR-3665 miR-1915-3p miR-4530
(validated from panel of 30 miRNAs)
miR-9/let-7e, miR-7/miR-451, miR335-5p/let-5e (FTD) miR-206/miR-338-3p, miR-9/miR-129-3p, miR-335-5p/miR-338-3p (ALS)miR-127-3pmiR-663a miR-502-3p miR-206Panels of 20, 147, 121 miRNAs for each cohortmiR-34a-5p miR-345-5p miR-200c-3p miR-10a-3p
  • *in serum.

  • †in plasma.

  • SOD1, FUS, C9orf72, PFN1.

  • §C9orf72, MAPT, GRN, TBK1.

  • ALS, amyotrophic lateral sclerosis; FTD, frontotemporal dementia; miRNA, microRNA; qRT-PCR, quantitative real-time PCR; RNA-seq, RNA sequencing.